Dadra & Nagar Haveli Chemists & Druggists Alianz Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -1.38%
(FY 2021)
- Profit 3.40%
(FY 2021)
- Ebitda 0.41%
(FY 2021)
- Net Worth -170.46%
(FY 2021)
- Total Assets -60.74%
(FY 2021)
About Dadra & Nagar Haveli Chemists & Druggists Alianz
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jigesh Patel and Ilaben Patel serve as directors at the Company.
- CIN/LLPIN
U24230DN2010PTC000307
- Company No.
000307
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jan 2010
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Dadra & Nagar Haveli, Dadra & Nagar Haveli, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dadra & Nagar Haveli Chemists & Druggists Alianz?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jigesh Patel  | Additional Director | 31-Mar-2022 | Current |
| Ilaben Patel | Additional Director | 31-Mar-2022 | Current |
Financial Performance of Dadra & Nagar Haveli Chemists & Druggists Alianz.
Dadra & Nagar Haveli Chemists & Druggists Alianz Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 1.38% decrease. The company also saw a slight improvement in profitability, with a 3.4% increase in profit. The company's net worth observed a substantial decline by a decrease of 170.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dadra & Nagar Haveli Chemists & Druggists Alianz?
In 2021, Dadra & Nagar Haveli Chemists & Druggists Alianz had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pratik Alloys Private LimitedActive 19 years 6 monthsJigesh Patel and Ilaben Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dadra & Nagar Haveli Chemists & Druggists Alianz?
Unlock and access historical data on people associated with Dadra & Nagar Haveli Chemists & Druggists Alianz, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dadra & Nagar Haveli Chemists & Druggists Alianz, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dadra & Nagar Haveli Chemists & Druggists Alianz's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
